GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GlaxoSmithKline Consumer Nigeria PLC (NSA:GLAXOSMITH) » Definitions » Cash Conversion Cycle

GlaxoSmithKline Consumer Nigeria (NSA:GLAXOSMITH) Cash Conversion Cycle : 122.37 (As of Jun. 2023)


View and export this data going back to 2001. Start your Free Trial

What is GlaxoSmithKline Consumer Nigeria Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

GlaxoSmithKline Consumer Nigeria's Days Sales Outstanding for the three months ended in Jun. 2023 was 81.04.
GlaxoSmithKline Consumer Nigeria's Days Inventory for the three months ended in Jun. 2023 was 111.76.
GlaxoSmithKline Consumer Nigeria's Days Payable for the three months ended in Jun. 2023 was 70.43.
Therefore, GlaxoSmithKline Consumer Nigeria's Cash Conversion Cycle (CCC) for the three months ended in Jun. 2023 was 122.37.


GlaxoSmithKline Consumer Nigeria Cash Conversion Cycle Historical Data

The historical data trend for GlaxoSmithKline Consumer Nigeria's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlaxoSmithKline Consumer Nigeria Cash Conversion Cycle Chart

GlaxoSmithKline Consumer Nigeria Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only 154.19 175.27 13.42 13.66 130.93

GlaxoSmithKline Consumer Nigeria Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 161.88 163.90 168.16 141.51 122.37

Competitive Comparison of GlaxoSmithKline Consumer Nigeria's Cash Conversion Cycle

For the Drug Manufacturers - General subindustry, GlaxoSmithKline Consumer Nigeria's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GlaxoSmithKline Consumer Nigeria's Cash Conversion Cycle Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, GlaxoSmithKline Consumer Nigeria's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where GlaxoSmithKline Consumer Nigeria's Cash Conversion Cycle falls into.



GlaxoSmithKline Consumer Nigeria Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

GlaxoSmithKline Consumer Nigeria's Cash Conversion Cycle for the fiscal year that ended in Dec. 2022 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=57.4+96.78-23.25
=130.93

GlaxoSmithKline Consumer Nigeria's Cash Conversion Cycle for the quarter that ended in Jun. 2023 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=81.04+111.76-70.43
=122.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


GlaxoSmithKline Consumer Nigeria  (NSA:GLAXOSMITH) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


GlaxoSmithKline Consumer Nigeria Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of GlaxoSmithKline Consumer Nigeria's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


GlaxoSmithKline Consumer Nigeria (NSA:GLAXOSMITH) Business Description

Traded in Other Exchanges
N/A
Address
No. 1, Industrial Avenue, Ilupeju, P.M.B. 21218, Ikeja, GSK House, Lagos, NGA
GlaxoSmithKline Consumer Nigeria PLC is a healthcare company that researches, develops, and manufactures pharmaceutical medicines, vaccines, and consumer healthcare products. The company has two reportable segments, the Consumer Healthcare segment consisting of oral care, over-the-counter (OTC) medicines, and nutritional healthcare; and the Pharmaceuticals segment consisting of vaccines and prescription drugs. The company's product line includes panadol, Andrews liver salt, Macleans, ampiclox, Sensodyne, and others. The generates maximum revenue from the Pharmaceuticals segment.

GlaxoSmithKline Consumer Nigeria (NSA:GLAXOSMITH) Headlines

No Headlines